Kiora Pharmaceuticals Inc expected to post a loss of 35 cents a share - Earnings Preview

Kiora Pharmaceuticals

03/11/2023 19:11

* Kiora Pharmaceuticals Inc  KPRX.OQ   KPRX.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Kiora
Pharmaceuticals Inc
is for a loss of 35 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kiora
Pharmaceuticals Inc is $2​, above​ its last closing price
of $0.61. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.74       -1.07      -0.79     Beat    25.9
 Mar. 31 2023  -1.71       -1.68      -1.00     Beat    40.7
 Dec. 31 2022  -2.23       -2.46      -1.76     Beat    28.6​
 Sep. 30 2022  -3.68       -3.83      -6.03     Missed  -57.3
 ​​Jun.        -8.00       -8.00      -7.20     Beat    10
 30 2022                                                
 Mar. 31 2022  -9.40       -9.40      -10.80    Missed  -14.9​
 Dec. 31 2021              -9.20      -26.47    Missed  -187.7
 Sep. 30 2021  -13.23      -13.47     -11.60    Beat    13.9
 This summary was machine generated November 3 at 19:11 GMT.  All
figures in US dollars  unless otherwise stated